CJC-1295 and Tesamorelin Together: What Is Known

CJC-1295 and Tesamorelin taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · 3 Oct 2026 · DisclosureUpdated 3 Oct 2026

GHRH analogNot FDA approved · research chemicalCJC-1295CJC-1295, a GHRH analog; in healthy adults a single injection produced dose-dependent rises in mean plasma GH of 2- to 10-fold and in IGF-I of 1.5- to 3-fold.^[5]Growth hormoneGHRH analogFDA approved (Egrifta)TesamorelinFDA-approved GHRH analog (Egrifta) for excess abdominal fat in HIV-associated lipodystrophy; visceral fat fell 15.2% versus a 5.0% rise with placebo in a randomized trial.^[15]Growth hormone

Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 15 results, 2 Oct 2026).

We have no sourced data on taking these two together. Ask the prescriber who manages both.

Each component

Side by side

Showing 8 of 14 fields where the two differ. Class, Category, PCAC vote, Jul 2026, WADA, Anti-doping detection, Evidence strength are the same or both unknown.

Field	CJC-1295	Tesamorelin
Class	GHRH analog	GHRH analog
Also called	CJC, mod GRF, GRF 1-29	tesa, Egrifta
Category	Growth hormone	Growth hormone
FDA status	Not FDA approved · research chemical	FDA approved (Egrifta)
PCAC vote, Jul 2026	Not on the Jul 2026 agenda	Not on the Jul 2026 agenda
WADA	Prohibited by WADA (S2.2.4)CJC-1295 is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times.	Prohibited by WADA (S2.2.4)Tesamorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. Tesamorelin is also an FDA-approved medicine; an athlete would need a therapeutic use exemption.
Anti-doping detection	A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973 Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524	A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973 Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524
Half-life	No published half-life foundPubMed search, 2 Oct 2026	11 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR)
Evidence strength	Human RCT evidence, 4 of 4Strongest: The Journal of clinical endocrinology and metabolism 2006, PMID 16352683	Human RCT evidence, 4 of 4Strongest: eNeurologicalSci 2026, PMID 42382101
Human studies we summarised	4 human (1 randomized or controlled) of 7 summarised	11 human (11 randomized or controlled) of 12 summarised
Typical study doses	Four ascending single doses (first study); two or three weekly or biweekly doses (second study), single, weekly or biweeklyThe Journal of clinical endocrinology and metabolism 2006, PMID 16352683 60 or 90 microg/kg CJC-1295 (single injection), singleThe Journal of clinical endocrinology and metabolism 2006, PMID 17018654 2 microg CJC-1295, every 24, 48 or 72 hAnimal · mouse · American journal of physiology. Endocrinology and metabolism 2006, PMID 16822960	1 mg tesamorelin, not statedeNeurologicalSci 2026, PMID 42382101 2 mg tesamorelin, once dailyThe lancet. HIV 2019, PMID 31611038 tesamorelin (dose not stated), not statedThe Journal of frailty & aging 2019, PMID 31237318
Vial sizes sold	2 mg, 5 mg, 10 mg	2 mg, 5 mg, 10 mg, 20 mg
US searches per month	60,500 · +49% searches	165,000 · +188% searches
Named in FDA warning letters, 2026	Not in the letters we track	Yes (24 Aug 2026)

Related tools

CJC-1295 vs Tesamorelin

Choosing between the two rather than combining them? The comparison lines them up field by field.

Open the comparison

ComparisonTesamorelin vs CJC-1295

What people search

tesamorelin and cjc 1295 together110/mo
tesamorelin and cjc 1295110/mo
cjc 1295 tesamorelin110/mo
cjc 1295 with tesamorelin70/mo
cjc 1295 and tesamorelin70/mo
tesamorelin with cjc 129540/mo

US monthly searches, Google Keyword Planner, Oct 2026. Shown so you can see which questions this page answers.

Sources

1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
3An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
4Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
5Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
6Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism · 2006PMID 17018654Accessed 2 Oct 2026
7Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.American journal of physiology. Endocrinology and metabolism · 2006PMID 16822960Accessed 2 Oct 2026
8PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
9PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
10EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
11The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
12Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
13The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
14PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
15Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026

Found an error? Report a correction.